Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 7/2015

01.07.2015 | Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Lipid Effects and Cardiovascular Disease Risk Associated with Glucose-Lowering Medications

verfasst von: Barbara E. Stähli, Catherine Gebhard, Jean-Claude Tardif

Erschienen in: Current Cardiology Reports | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Diabetes is a global epidemic, associated with a high burden of complications and 4.6 million deaths annually worldwide. As a result of decreasing levels of physical activity and increasing rates of obesity, diabetes is shifting from a disease affecting the elderly to one that affects younger patients or even children. Thus, aggressive treatment and optimal control of risk factors is the key to improve outcomes in those patients. Accumulating evidence of the cardiovascular and lipid effects of glucose-lowering medications suggest that treatment efficacy in diabetes can be further improved. This review provides an overview of the lipid effects and cardiovascular disease risk of current anti-diabetic medications and highlights opportunities and challenges in clinical practice.
Literatur
1.
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.PubMedCrossRef
2.
Preis SR, Pencina MJ, Mann DM, et al. Early-adulthood cardiovascular disease risk factor profiles among individuals with and without diabetes in the Framingham Heart Study. Diabetes Care. 2013;36:1590–6.PubMedCentralPubMedCrossRef
3.
Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–44.PubMedCrossRef
4.
Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J. 1998;316:823–8.CrossRef
5.
Tan CE, Chew LS, Chio LF, et al. Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res Clin Pract. 2001;51:107–14.PubMedCrossRef
6.
Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150–9.PubMedCrossRef
7.••
Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73:327–39. This article provides an excellent overview of the characteristics of diabetic dyslipidemia including pathophysiological aspects and clinical implications.PubMedCrossRef
8.
Buse JB, Tan MH, Prince MJ, et al. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6:133–56.PubMedCrossRef
9.
DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541–9.PubMedCrossRef
10.
Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996;19:64–6.PubMedCrossRef
11.
Lund SS, Tarnow L, Astrup AS, et al. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab. 2009;11:966–77.PubMedCrossRef
12.
Tessier D, Maheux P, Khalil A, et al. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metab Clin Exp. 1999;48:897–903.PubMedCrossRef
13.
Hollenbeck CB, Johnston P, Varasteh BB, et al. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria. Diabete Metab. 1991;17:483–9.PubMed
14.
Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550–4.PubMedCrossRef
15.
Campbell IW, Menzies DG, Chalmers J, et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab. 1994;20:394–400.PubMed
16.
Belcher G, Lambert C, Goh KL, et al. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract. 2004;58:833–7.PubMedCrossRef
17.
Wulffele MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256:1–14.PubMedCrossRef
18.
Bhalla RC, Toth KF, Tan E, et al. Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am J Hypertens. 1996;9:570–6.PubMedCrossRef
19.
Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344–50.PubMedCrossRef
20.
Yin M, van der Horst IC, van Melle JP, et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011;301:H459–68.PubMedCrossRef
21.
Solskov L, Lofgren B, Kristiansen SB, et al. Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol. 2008;103:82–7.PubMedCrossRef
22.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.CrossRef
23.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.PubMedCrossRef
24.•
Solini A, Penno G, Bonora E, et al. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. J Am Geriatr Soc. 2013;61:1253–61. This study demonstrates that metformin treatment is independently associated with a lower prevalence of cardiovascular disease independent of age and renal function.PubMedCrossRef
25.
Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170:1892–9.PubMedCrossRef
26.•
Aguilar D, Chan W, Bozkurt B, et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011;4:53–8. This study demonstrates that metformin therapy is associated with lower rates of mortality in diabetic patients with heart failure.PubMedCentralPubMedCrossRef
27.
Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268:423–6.PubMedCrossRef
28.
Johanson EH, Jansson PA, Gustafson B, et al. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes. Diabetes Metab Res Rev. 2005;21:376–81.PubMedCrossRef
29.
Salman S, Salman F, Satman I, et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin. 2001;16:296–306.PubMedCrossRef
30.
Jeppesen J, Zhou MY, Chen YD, et al. Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM. Diabetologia. 1994;37:781–7.PubMedCrossRef
31.
Waysbort J, Regitz G, Chaimowitz D, et al. Effects of glibenclamide on serum lipids, lipoproteins, thromboxane, beta-thromboglobulin, and prostacyclin in non-insulin-dependent diabetes mellitus. Clin Ther. 1988;10:358–71.PubMed
32.
Rizzo MR, Barbieri M, Grella R, et al. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabetes Metab. 2005;31:255–60.PubMedCrossRef
33.••
Monami M, Vitale V, Ambrosio ML, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther. 2012;29:736–46. This meta-analysis investigates the effects of different glucose-lowering drugs on lipid profiles.PubMedCrossRef
34.
Zhang F, Xiang H, Fan Y, et al. The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine. 2013;44:648–58.PubMedCrossRef
35.
Roumie CL, Huizinga MM, Liu X, et al. The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort. Pharmacoepidemiol Drug Saf. 2011;20:36–44.PubMedCrossRef
36.
Konya H, Hasegawa Y, Hamaguchi T, et al. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metab Clin Exp. 2010;59:1294–9.PubMedCrossRef
37.
Manzella D, Grella R, Abbatecola AM, et al. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care. 2005;28:366–71.PubMedCrossRef
38.
Esposito K, Giugliano D, Nappo F, et al. Campanian Postprandial Hyperglycemia Study G. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214–9.PubMedCrossRef
39.•
Phung OJ, Schwartzman E, Allen RW, et al. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013;30:1160–71. This study suggests that sulfonylurea treatment may elevate the risk of cardiovascular disease in diabetic patients.PubMedCrossRef
40.•
Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900–8. This study suggests that monotherapy with the most used insulin secretagogues is associated with increased mortality and cardiovascular risk as compared with metformin treatment.PubMedCrossRef
41.
Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ : Can Med Assoc J. 2006;174:169–74.
42.
Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157:601–10.PubMedCrossRef
43.
Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30:389–94.PubMedCrossRef
44.
Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–84.PubMedCrossRef
45.
Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. J Am Med Assoc. 2006;296:2572–81.CrossRef
46.
Khanolkar MP, Morris RH, Thomas AW, et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis. 2008;197:718–24.PubMedCrossRef
47.
Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab. 1999;1:165–72.PubMedCrossRef
48.
Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43:278–84.PubMedCrossRef
49.
Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280–8.PubMedCrossRef
50.
Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24:308–15.PubMedCrossRef
51.
Atamer Y, Atamer A, Can AS, et al. Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus. Braz J Med Biol Res. 2013;46:528–32.PubMedCentralPubMedCrossRef
52.
Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30:2458–64.PubMedCrossRef
53.
Suh DC, Lee DH, McGuire M, et al. Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients. Curr Med Res Opin. 2011;27:1623–33.PubMedCrossRef
54.
Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab. 2007;9:512–20.PubMedCrossRef
55.
Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547–54.PubMedCrossRef
56.
Derosa G, D’Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J. 2007;37:79–86.PubMedCrossRef
57.•
Nicholls SJ, Tuzcu EM, Wolski K, et al. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. J Am Coll Cardiol. 2011;57:153–9. This study shows that favorable effects of pioglitazone on the triglyceride/HDL cholesterol ratio correlate with delayed atheroma progression in diabetic patients.PubMedCrossRef
58.
Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129–36.PubMedCrossRef
59.
Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. J Am Med Assoc. 2007;298:2634–43.CrossRef
60.
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. J Am Med Assoc. 2007;298:1189–95.CrossRef
61.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.PubMedCrossRef
62.
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–89.PubMedCrossRef
63.
Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31:824–31.PubMedCentralPubMedCrossRef
64.
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125–35.PubMedCrossRef
65.
Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374(9684):126–35.PubMedCrossRef
66.•
Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. J Am Med Assoc. 2014;311:1515–25. This large randomized trial has shown that the dual PPAR agonist aleglitazar did not improve clinical outcomes in patients with diabetes and a recent acute coronary syndrome despite favorable effects on glycemic control and the lipid profile.CrossRef
67.
Shinoda Y, Inoue I, Nakano T, et al. Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance. Metab Clin Exp. 2006;55:935–9.PubMedCrossRef
68.
Patel YR, Kirkman MS, Considine RV, et al. Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes. Diabetes Metab Res Rev. 2013;29:582–91.PubMedCentralPubMed
69.
Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35:1073–8.PubMedCrossRef
70.
Liao Y, Takashima S, Zhao H, et al. Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice. Cardiovasc Res. 2006;70:107–16.PubMedCrossRef
71.
Iwasa M, Kobayashi H, Yasuda S, et al. Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits. J Cardiovasc Pharmacol. 2010;55:625–34.PubMedCrossRef
72.
Hiki M, Shimada K, Kiyanagi T, et al. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J. 2010;74:1471–8.PubMedCrossRef
73.
Emoto T, Sawada T, Hashimoto M, et al. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol. 2012;109:42–6.PubMedCrossRef
74.
Ogawa S, Takeuchi K, Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diabetes Obes Metab. 2004;6:384–90.PubMedCrossRef
75.
Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med. 1997;103:483–90.PubMedCrossRef
76.
Shrivastava A, Chaturvedi U, Singh SV, et al. Lipid lowering and antioxidant effect of miglitol in triton treated hyperlipidemic and high fat diet induced obese rats. Lipids. 2013;48:597–607.PubMedCrossRef
77.
Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. J Am Med Assoc. 2003;290:486–94.CrossRef
78.
Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.PubMedCrossRef
79.
van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28:154–63.PubMedCrossRef
80.
Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234–43.PubMedCrossRef
81.
Ye Y, Qian J, Castillo AC, et al. Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013;304:H131–41.PubMedCrossRef
82.
Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209–15.PubMedCrossRef
83.
Gaspari T, Liu H, Welungoda I, et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab Vasc Dis Res. 2011;8:117–24.PubMedCrossRef
84.
Rizzo M, Chandalia M, Patti AM, et al. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014;13:49.PubMedCentralPubMedCrossRef
85.
Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–5.PubMedCrossRef
86.
Varanasi A, Patel P, Makdissi A, et al. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors. Endocr Pract : Off J Am Coll Endocrinol Am Assoc Clin Endocrinologists. 2012;18:140–5.CrossRef
87.
Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003;21:1125–35.PubMedCrossRef
88.
Koren S, Shemesh-Bar L, Tirosh A, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther. 2012;14:561–7.PubMedCrossRef
89.
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. J Am Med Assoc. 2007;298:194–206.CrossRef
90.
Tokuda M, Katsuno T, Ochi F, et al. Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes. Endocr J. 2014;61:365–72.PubMedCrossRef
91.
Schwartz EA, Koska J, Mullin MP, et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis. 2010;212:217–22.PubMedCrossRef
92.
Xiao C, Bandsma RH, Dash S, et al. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol. 2012;32:1513–9.PubMedCrossRef
93.
Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275–86.PubMed
94.
Peskin BR, Shcheprov AV, Boye KS, et al. Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. Diabetes Obes Metab. 2011;13:921–7.PubMedCrossRef
95.
Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16:30–7.PubMedCrossRef
96.
Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27 Suppl 3:57–64.PubMedCrossRef
97.
Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011;2011:215764.PubMedCentralPubMed
98.•
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35. This study demonstrates that among diabetic patients with recent acute coronary syndrome, rates of ischemic cardiovascular events are not increased with alogliptin as compared with placebo.PubMedCrossRef
99.•
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26. This study demonstrates that DPP-4 inhibition with saxagliptin does not alter rates of ischemic events, although rates of hospitalization for heart failure were increased.PubMedCrossRef
100.
Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis : NMCD. 2014;24(7):689–97.PubMedCrossRef
101.
Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551–9.PubMedCrossRef
102.
Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. A randomized trial. Ann Intern Med. 2012;156:405–15.PubMedCrossRef
103.
Parikh S, Wilding J, Jabbour S, Hardy E. Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. Int J Clin Pract. 2015;69:186–98.PubMedCrossRef
104.
Bode B, Stenlöf K, Harris S, Sullivan D, Fung A, Usiskin K, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17:294–303.PubMedCrossRef
105.
Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17(6):591–8.
106.
Gerstein HC, Bosch J, Dagenais GR, et al. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28.PubMedCrossRef
Metadaten
Titel
Lipid Effects and Cardiovascular Disease Risk Associated with Glucose-Lowering Medications
verfasst von
Barbara E. Stähli
Catherine Gebhard
Jean-Claude Tardif
Publikationsdatum
01.07.2015
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 7/2015
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-015-0608-6

Weitere Artikel der Ausgabe 7/2015

Current Cardiology Reports 7/2015 Zur Ausgabe

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Safety of Implanted Cardiac Devices in an MRI Environment

Cardio-Oncology (SA Francis, Section Editor)

Cardiotoxicity due to Chemotherapy: the Role of Biomarkers

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Impact of Sex and Ethnicity on Arrhythmic Risk

Interventional Cardiology (S Rao, Section Editor)

Limb Ischemia: Cardiovascular Diagnosis and Management from Head to Toe

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Dyslipidemia and Cardiovascular Disease in Women

Cardiac PET, CT, and MRI (SE Petersen, Section Editor)

The Value of Cardiovascular Magnetic Resonance in Heart Transplant Patients

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise